XML 75 R59.htm IDEA: XBRL DOCUMENT
v3.10.0.1

License and Other Agreements (Details) € in Millions, $ in Millions | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | ---
Oct. 31, 2016 USD ($) | Dec. 31, 2014 USD ($) | Jul. 31, 2014 | Feb. 28, 2014 | Apr. 30, 2008 EUR (€) | Dec. 31, 2018 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2009 USD ($) | Dec. 31, 2004 USD ($) | Oct. 31, 2017 USD ($) | Sep. 30, 2015 USD ($)
PARI Agreement |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Initial term of contract manufacturing agreement |  |  | 15 years |  |  |  |  |  |  |  |
Additional term of contract manufacturing agreement |  |  | 5 years |  |  |  |  |  |  |  |
PARI Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Future milestone payments | € |  |  |  |  | € 0.5 |  |  |  |  |  |
PARI Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Written notice period required for termination of contract manufacturing agreement |  |  | 1 year |  |  |  |  |  |  |  |
CFFT |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Compensation earned under research funding agreements with CFFT |  |  |  |  |  |  |  | $ 2.2 | $ 1.7 |  |
Royalty payable on approval of ARIKAYCE as commercialized drug |  |  |  |  |  | $ 13.4 |  |  |  |  |
Royalty payment period |  |  |  |  |  | 3 years |  |  |  |  |
Period for meeting sales milestones for additional royalty payments |  |  |  |  |  | 5 years |  |  |  |  |
Royalty payable on meeting certain sales milestones |  |  |  |  |  | $ 3.9 |  |  |  |  |
Therapure |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Initial term of contract manufacturing agreement |  |  |  | 5 years |  |  |  |  |  |  |
Period of each automatic renewal of contract manufacturing agreement |  |  |  | 2 years |  |  |  |  |  |  |
Written notice period required for termination of contract manufacturing agreement |  |  |  | 2 years |  |  |  |  |  |  |
Agreement with SynteractHCR, Inc. for 212 Study |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Commitment To Pay Aggregate Costs From Agreement |  | $ 48.0 |  |  |  |  |  |  |  |  |
Fill/Finish Agreement |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Minimum obligation |  |  |  |  |  |  |  |  |  |  | $ 2.7
Extension period |  |  |  |  |  | 2 years |  |  |  |  |
Period prior to expiration for extension |  |  |  |  |  | 1 year |  |  |  |  |
License Agreement with AstraZeneca |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Royalty payment | $ 35.0 |  |  |  |  |  |  |  |  |  |
License Agreement with AstraZeneca | Research and development expenses |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  | $ 30.0 |  |  |  |
License Agreement with AstraZeneca | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Aggregate payment upon the achievement of certain clinical milestones | 85.0 |  |  |  |  |  |  |  |  |  |
Additional contingent payments upon second indication to develop INS1007 | 42.5 |  |  |  |  |  |  |  |  |  |
Supply Agreement with Patheon UK Limited |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Agreement to purchase raw materials and fixed assets |  |  |  |  |  |  |  |  |  | $ 60.0 |
Agreement With Syneos Health For Willow Study |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Commitment To Pay Aggregate Costs From Agreement |  | $ 21.0 |  |  |  |  |  |  |  |  |
License and Service | License Agreement with AstraZeneca |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Annual net sales | $ 1,000.0 |  |  |  |  |  |  |  |  |  |
Milestone, New Drug Application | PARI Agreement |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
PARI milestone upon FDA approval | € |  |  |  |  | 1.0 |  |  |  |  |  |
Milestone, FDA Approval | PARI Agreement |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
PARI milestone upon FDA approval | € |  |  |  |  | € 1.5 |  |  |  |  |  |

X
- Definition Amount of royalty payments if entity meets certain milestones under a research and development agreement. + References No definition available. + Details
Name: | insm_AdditionalRoyaltyGuaranteesCommitmentsAmount
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the additional extension period of contract manufacturing agreement. + References No definition available. + Details
Name: | insm_AdditionalTermOfContractManufacturingAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate additional series of contingent milestone payments if selects to develop for second indication. + References No definition available. + Details
Name: | insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Milestone Payment + References No definition available. + Details
Name: | insm_CollaborativeArrangementMilestonePayment
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of upfront payment paid during the period under collaborative arrangement. + References No definition available. + Details
Name: | insm_CollaborativeArrangementUpfrontPayment
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the extension period under the terms of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | insm_CommercialServicesAgreementExtensionPeriod
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period prior to the expiration of the agreement in which an agreement for extension may be entered into upon mutual agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the minimum obligation due under the terms of the agreement. + References No definition available. + Details
Name: | insm_CommercialServicesAgreementMinimumObligation
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Future Milestone Payments + References No definition available. + Details
Name: | insm_FutureMilestonePayments
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Implementation And Management Services Agreement, Aggregate Costs + References No definition available. + Details
Name: | insm_ImplementationAndManagementServicesAgreementAggregateCosts
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the initial period of contract manufacturing agreement. + References No definition available. + Details
Name: | insm_InitialTermOfContractManufacturingAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Manufacture And Supply Agreement, Estimated Costs + References No definition available. + Details
Name: | insm_ManufactureAndSupplyAgreementEstimatedCosts
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate payment upon the achievement of certain clinical milestones. + References No definition available. + Details
Name: | insm_PaymentsUponAchievementOfClinicalMilestonesAmount
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period for meeting sales milestones for additional royalty payments after the drug is commercialized. + References No definition available. + Details
Name: | insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period of each automatic renewal of contract manufacturing agreement. + References No definition available. + Details
Name: | insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period for royalty payments under a research and development agreement. + References No definition available. + Details
Name: | insm_RoyaltyPaymentPeriod
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the written notice period required for termination of contract manufacturing agreement by either party. + References No definition available. + Details
Name: | insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount the entity has committed to make for future royalty guarantees. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 928 -SubTopic 440 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013 + Details
Name: | us-gaap_RoyaltyGuaranteesCommitmentsAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_TherapureBiopharmaIncContractManufacturingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_AgreementWithSynteractHCRInc.For212StudyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_CommercialFilVFinishServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_SupplyAgreementWithPatheonUKLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_AgreementWithSyneosHealthForWillowStudyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | insm_MilestonePaymentAxis=insm_MilestoneNewDrugApplicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | insm_MilestonePaymentAxis=insm_MilestoneFDAApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |